Purpose: Lymphadenectomy is a well established practice for many urological malignancies but its role in renal cell carcinoma is less clear. Our primary objective was to determine whether lymphadenectomy impacted survival in patients with fully resected, high risk renal cell carcinoma. Materials and Methods: Patients with fully resected, high risk, nonmetastatic renal cell carcinoma were randomized to adjuvant sorafenib, sunitinib or placebo in the ASSURE (Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma) trial. Lymphadenectomy was performed for cNþ disease or at surgeon discretion. Patients treated with lymphadenectomy were compared to patients in the trial who did not undergo lymphadenectomy. The primary outcome was overall survival associated with lymphadenectomy. Secondary outcomes were disease free survival, factors associated with performing lymphadenectomy and surgical complications. Results: Of the 1,943 patients in ASSURE 701 (36.1%) underwent lymphadenectomy, including all resectable patients with cNþ and 30.1% of those with cN0 disease. A median of 3 lymph nodes (IQR 1e8) were removed and the rate of pNþ disease in the lymphadenectomy group was 23.4%. There was no overall survival benefit for lymphadenectomy relative to no lymphadenectomy (HR 1.14, 95% CI 0.93e1.39, p ¼ 0.20). In patients with pNþ disease who underwent lymphadenectomy no improvement in overall or disease-free survival was observed for Accepted for publication July 10, 2017. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
LYMPHADENECTOMY in the presence of clinically negative lymph nodes (cN0) is a well established practice for most genitourinary malignancies, including prostate, bladder and penile cancers. Yet current guidelines for RCC recommend LND only in the presence of clinically suspicious nodes. 4, 5 Retrospective analyses of high risk RCC offer conflicting evidence of an oncologic benefit for LND. 6, 7 A single randomized trial, EORTC 30881, demonstrated no survival advantage for LND in the setting of localized cN0 RCC. However, since most patients in this trial had a low rate of pathological lymph node involvement (4%) and low grade (77%), low stage (68% stage I-II) disease, this population may not have represented the cohort most likely to benefit. 8 Thus, defining the ideal patient in whom LND would be beneficial remains elusive.
The survival impact of adjuvant systemic therapy in patients with high risk RCC is similarly controversial. Historically adjuvant radiotherapy, hormonal therapy and cytotoxic chemotherapy have demonstrated no measureable survival benefit in this population. 9 Two recent trials, S-TRAC (Sunitinib as Adjuvant Treatment for Patients at High Risk of Recurrence of Renal Cell Carcinoma Following Nephrectomy) and ASSURE, provided disparate evidence of benefit with the former demonstrating improved DFS in patients who received adjuvant sunitinib and the latter showing no DFS difference between adjuvant sunitinib or sorafenib vs placebo. 10, 11 Since the goal of adjuvant systemic therapy is to eradicate micrometastatic disease after surgery, a multimodal approach, including the removal of clinically suspicious lymph nodes at nephrectomy followed by systemic therapy, may better select patients for the adjuvant approach.
We performed a secondary analysis of the ASSURE (ECOG-ACRIN E2805) randomized trial, 11 focusing on the role of LND in patients with high risk, fully resected RCC. Our primary objective was to assess whether LND impacted OS in these patients. Secondary objectives were to examine differences in DFS conferred by LND, the oncologic benefit of adjuvant therapy in patients with pNþ disease who underwent LND, the extent of LND performed, factors predicting LND and complications associated with LND.
PATIENTS AND METHODS

Patient Characteristics and Setting
The methodology of the ASSURE trial was recently published. 11 Briefly, after nephrectomy patients at high risk were randomly assigned 1:1:1 to sunitinib, sorafenib or placebo from April 2006 to December 2010. The primary outcome measure was intent to treat DFS between each experimental group and the placebo group. Patients at high risk were defined as having pT1b G3-4 N0 (or pNX with cN0) M0 to T (any) G (any) Nþ M0. In patients with cNþ disease complete resection was required. Of the patients 98.5% enrolled in the study postoperatively.
Surgeons completed a form after surgery documenting 3 categories, including 1) surgical performance and staging, including type of surgerydradical vs partial nephrectomy, laterality, approachdopen vs laparoscopic, adrenalectomyd yes vs no vs partial, lymphadenectomydyes vs no, grossly positive yes vs no and extranodal extension yes vs no), surgical margin status, histological type, presence of sarcomatoid features and pathological tumor stage, 2) intraoperative surgical complications and 3) extent of LND if performed. Although the protocol required the removal of all suspicious nodes, the performance of LND was at the discretion of the operative surgeon and templates were not standardized. Surgical complication reporting included wound infection, wound dehiscence and/ or fistula, pneumonia, cardiopulmonary complication, hemorrhage, renal failure and specified other.
Paraffin embedded tumor samples were required for central review. Patients had to be treatment na€ ıve for kidney cancer, have good ECOG performance status (0 or 1), and have normal liver and hematological function. The criterion for kidney function was creatinine clearance greater than 30 ml per minute. The treatment regimen was 54 weeks of sunitinib orally 50 mg per day for the first 28 days of each 6-week cycle, sorafenib orally 400 mg twice daily throughout all cycles or placebo. Study participation required written informed consent.
Statistical Analysis
The Fisher and Mehta exact tests were used to test for univariate associations of surgery type with patient characteristics, disease and surgical course. For continuous variables the Wilcoxon rank sum test was applied. A logistic regression model was created to explore multivariable associations with LND. Cox proportional hazards models were used to identify factors associated with an increased risk of OS and DFS. The Collet model building methods were also applied. 12 Factors that were significant at p ¼ 0.05 on univariate analysis were retained in the model. Because there were no statistically significant differences in OS or DFS among patients treated with sorafenib, sunitinib or placebo, 11 patients from all arms were included in analysis.
RESULTS
Surgical forms were available for 1,942 of the 1,943 patients (99.9%). LND was performed in 701 of enrolled patients (36.1%). A median of 3 lymph nodes (IQR 1e8) were examined. Only 124 LNDs (17.7%) yielded greater than 10 nodes. Disease was pNþ in 164 cases (23.4%), of which 99.2% were deemed grossly positive. Patients with cNþ disease were more likely to undergo LND than those with cN0 disease (99.4% vs 30.1%, p <0.001). Only 10 patients (1.98%) with cN0 disease who underwent LND had pNþ disease, suggesting high negative predictive value of a benign-appearing lymph node on computerized tomography. Only 1 patient with cNþ had unresectable lymphadenopathy and did not undergo LND. There were no differences in reported surgical complications between the groups (14.2% for LND vs 13.4%, p ¼ 0.63). fig. 1, B) . Survival analyses were performed to consider the impact of adjuvant systemic therapy in the subset of patients with pNþ disease who underwent LND. There was no difference in 5-year OS in the sunitinib arm (45.7%, 95% CI 32.9e63.6, p ¼ 0.113) or the sorafenib arm (63.7%, 95% CI 51.3e79.3, p ¼ 0.981) vs the placebo arm (64.8%, 95% CI 54.2e77.6, fig. 2,  A) . Moreover, median DFS in this subset did not differ in the sorafenib arm (21.6 months, 95% CI 13.7e48.4, p ¼ 0.633) vs the placebo arm (24.7 fig. 2, B) .
Lymph Node Dissection Category
DISCUSSION
These data quantify factors associated with the performance of LND during a randomized clinical trial of adjuvant therapy for RCC. Given that most patients were enrolled postoperatively, it seems likely that surgical decision making reflected current practice and was consistent with published guidelines. 4, 5 While LND was performed at the discretion of the operating surgeon, LND was almost universal in patients with cNþ disease and it was not routine in those with cN0 disease. The trial also corroborated the notion that regionally positive nodes are often plucked during surgery for high risk RCC rather than removed using standardized dissection templates. 13 Independent predictors and nomograms of pNþ disease in advanced RCC have been published to guide the decision to perform LND.
14e16 Preoperative factors associated with lymph node metastasis include ECOG PS 1 or greater, cN1 stage, increased lactate dehydrogenase, symptomatic presentation and greater tumor size. Pathological predictors of nodal involvement are Fuhrman grade 3-4, sarcomatoid component, tumor size 10 cm or greater, pT3 or pT4 tumor stage and the presence of histological tumor necrosis. While it is not clear that surgeons in the current study prospectively used these established criteria, sarcomatoid features and higher AJCC stage were associated with the performance of LND.
One concern regarding LND is the potential for increased postoperative complications. However, randomized trial data have not demonstrated an increased risk of LND associated complications. 8 Similarly our findings showed no difference in complication rates between patients who did and did not undergo LND. Therefore, it appears that LND carries an acceptable risk in patients during renal surgery performed by experienced retroperitoneal surgeons. Importantly these data were contextualized by limiting study eligibility to those who were well enough to be randomized 12 weeks after surgery. Therefore, any enrollment limiting major complications of LND may have been selected out.
The added oncologic benefit of LND in patients with high risk renal cell carcinoma remains unclear. EORTC 30881, the only randomized trial to date, demonstrated no improvement in time to progression or progression free-survival in patients who underwent LND. 8 EORTC 30881 has been criticized as being underpowered for its low lymph node positive rate in the LND arm (4%) and the preponderance of low grade (77%), low stage (68%) disease. Conversely retrospective analyses suggested that some patients at high risk may benefit from LND. 17, 18 However, no retrospective analysis has been able to definitively conclude that improvements in recurrence-free survival were due to LND rather than to the Will Rogers effect. 19 Moreover, a recently reported and well controlled, retrospective analysis using propensity scoring demonstrated no survival benefit attributable to LND in patients at high risk. 7 The eligibility limitations of our study posed similar problems with selection bias. Performance of LND was an unexpected predictor of earlier recurrence. The most logical explanation of this finding is that surgeons performed LND in patients with higher risk tumors and tumor risk was not adequately controlled in the multivariable model. The underpinnings of an OS benefit related to aggressive surgery in high risk RCC are derived from the tumor debulking and metastatectomy literature. 20, 21 In our study LND was independently associated with other markers of aggressive surgical resection such as open surgery, radical nephrectomy and adrenalectomy. Despite this we noted no improvement in OS in patients who underwent more aggressive surgical procedures, including LND. Similar findings have been described for other malignancies for which aggressive surgery is a mainstay in the multimodal management of advanced disease. 22 Given the recent results of the S-TRAC adjuvant RCC trial suggesting improved DFS in patients with high risk, clear cell RCC who received 1 year of adjuvant sunitinib, 10 one might expect the same in the highest risk patient group (ie pNþ) in ASSURE. The fact that we did not find improvement in DFS or OS in patients with fully resected pNþ disease who received adjuvant sorafenib or sunitinib may suggest incomplete understanding of the optimal patient population in which to deploy adjuvant systemic strategies. 23 The principle limitation of our study is selection bias since LND was not an eligibility or randomization requirement in this prospective clinical trial. While the decision to perform LND was surgeon dependent and patients with worse disease appear to have been preferentially selected, patients with any suspicion of cNþ required LND to be considered trial eligible. Therefore, unlike most retrospective studies in which selection bias may decrease the intensity of surgical interventions in patients at higher risk, the nature of this trial enriched the selected population, perhaps providing more powerful insights.
Also, although the trial protocol necessitated the removal of all clinically suspicious lymph nodes, LND templates were not standardized across surgeons. Coupled with the relatively low median lymph node yield, this lack of standardization may have influenced the results.
Further, the potential for recall bias existed since surgeons completed surgical surveys at the time of patient enrollment, which was up to 12 weeks after surgery in more than 95% of the patients enrolled. However, biases associated with the Hawthorne effect were essentially nonexistent for similar design related reasons, making this is an accurate representation of LND in current surgical practice for high risk RCC.
Finally, the fidelity of followup data related to complications and tumor recurrence were likely better in this prospective clinical trial than what would be expected in an institutional retrospective study.
The uncertain benefit of LND in patients with high risk RCC coupled with no apparent difference in complications at experienced centers offers appropriate equipoise for a clinical trial. Patients with high risk kidney tumors (cT2-3N0M0) could be randomized to no LND vs standard template LND 24 with DFS as a primary outcome and OS as 1 secondary outcome. A planned subanalysis could be performed in patients with high risk pathological features. Ideally such a trial could garner support from cooperative groups to answer this important clinical question.
CONCLUSIONS
Lymphadenectomy in patients with high risk, nonmetastatic RCC is safe and carries an acceptably low complication rate. However, the oncologic benefit of LND in this setting remains unproven and LND was not associated with an OS advantage in ASSURE. Therefore, it is important to consider that the risk of LND may outweigh the clinical benefit despite the relatively small incidence of associated complications. Moreover, even in patients with highest risk who have fully resected pNþ disease adjuvant therapy does not appear to confer improved survival. Future strategies to answer this question should include a prospective clinical trial designed to capture patients with high risk RCC.
